Artal Group S.A. Ascendis Pharma A/S Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $12.2 Million - $15.5 Million	101,100 New	101,100 $13.8 Million
Q3 2020 Nov 13, 2020	SELL	$134.29 - $154.32 $8.73 Million - $10 Million	-65,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $3.88 Million - $5.46 Million	-35,000 Reduced 35.0%	65,000 $9.61 Million
Q4 2019 Feb 13, 2020	SELL	$91.45 - $139.12 $4.57 Million - $6.96 Million	-50,000 Reduced 33.33%	100,000 $13.9 Million
Q2 2019 Aug 09, 2019	BUY	$107.11 - $132.09 $2.68 Million - $3.3 Million	25,000 Added 20.0%	150,000 $17.3 Million
Q1 2019 May 10, 2019	BUY	$62.15 - $129.99 $7.77 Million - $16.2 Million	125,000 New	125,000 $14.7 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.